| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Idiopathic Pulmonary Fibrosis | 66 | 2024 | 173 | 12.390 |
Why?
|
| Lung Diseases, Interstitial | 56 | 2024 | 216 | 10.510 |
Why?
|
| Pulmonary Fibrosis | 42 | 2024 | 175 | 10.160 |
Why?
|
| Arthritis, Rheumatoid | 23 | 2024 | 496 | 4.520 |
Why?
|
| Lung | 84 | 2025 | 3300 | 4.270 |
Why?
|
| Syndecan-2 | 6 | 2022 | 15 | 2.890 |
Why?
|
| Lung Injury | 8 | 2024 | 145 | 2.360 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 23 | 2024 | 1062 | 2.110 |
Why?
|
| Bleomycin | 22 | 2024 | 482 | 1.930 |
Why?
|
| Lung Transplantation | 18 | 2023 | 383 | 1.840 |
Why?
|
| Pulmonary Emphysema | 12 | 2023 | 159 | 1.780 |
Why?
|
| Lymphangioleiomyomatosis | 10 | 2023 | 24 | 1.610 |
Why?
|
| Fibroblasts | 23 | 2024 | 1656 | 1.580 |
Why?
|
| Biomarkers | 30 | 2024 | 5060 | 1.370 |
Why?
|
| Single-Cell Analysis | 7 | 2024 | 557 | 1.230 |
Why?
|
| Tomography, X-Ray Computed | 37 | 2025 | 7784 | 1.200 |
Why?
|
| Lung Diseases | 10 | 2025 | 755 | 1.180 |
Why?
|
| Mucin-5B | 10 | 2024 | 34 | 1.180 |
Why?
|
| Smoking | 20 | 2024 | 2555 | 1.170 |
Why?
|
| Alveolar Epithelial Cells | 7 | 2024 | 51 | 1.060 |
Why?
|
| Humans | 199 | 2025 | 270802 | 0.960 |
Why?
|
| Receptors, Interleukin-6 | 2 | 2021 | 65 | 0.920 |
Why?
|
| Vital Capacity | 8 | 2024 | 140 | 0.900 |
Why?
|
| Silicosis | 1 | 2023 | 6 | 0.890 |
Why?
|
| Transforming Growth Factor beta1 | 6 | 2024 | 294 | 0.860 |
Why?
|
| Primary Graft Dysfunction | 5 | 2023 | 35 | 0.840 |
Why?
|
| Indoles | 4 | 2021 | 1028 | 0.840 |
Why?
|
| Radiation Injuries | 2 | 2022 | 1470 | 0.820 |
Why?
|
| Tobacco Smoke Pollution | 3 | 2013 | 112 | 0.820 |
Why?
|
| Idiopathic Interstitial Pneumonias | 3 | 2024 | 13 | 0.810 |
Why?
|
| Carbon Monoxide | 3 | 2019 | 68 | 0.790 |
Why?
|
| Cryopreservation | 2 | 2020 | 151 | 0.780 |
Why?
|
| Pyridones | 4 | 2023 | 360 | 0.770 |
Why?
|
| Antimetabolites | 1 | 2021 | 76 | 0.760 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2022 | 3408 | 0.760 |
Why?
|
| Endoplasmic Reticulum Stress | 2 | 2019 | 202 | 0.750 |
Why?
|
| Pulmonologists | 2 | 2021 | 12 | 0.750 |
Why?
|
| Telomere | 7 | 2024 | 549 | 0.730 |
Why?
|
| Matrix Metalloproteinase 7 | 4 | 2016 | 33 | 0.700 |
Why?
|
| Emphysema | 4 | 2023 | 88 | 0.690 |
Why?
|
| Palmitic Acid | 1 | 2019 | 43 | 0.690 |
Why?
|
| Forced Expiratory Volume | 6 | 2018 | 327 | 0.680 |
Why?
|
| Animals | 63 | 2024 | 62048 | 0.680 |
Why?
|
| Endothelial Cells | 11 | 2023 | 1038 | 0.670 |
Why?
|
| Respiratory Function Tests | 15 | 2021 | 354 | 0.670 |
Why?
|
| Biological Specimen Banks | 1 | 2020 | 75 | 0.670 |
Why?
|
| Mice | 51 | 2024 | 35597 | 0.670 |
Why?
|
| Hyaluronic Acid | 5 | 2021 | 152 | 0.640 |
Why?
|
| Fibrosis | 10 | 2024 | 733 | 0.630 |
Why?
|
| Disease Progression | 16 | 2024 | 6855 | 0.630 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 3 | 2016 | 125 | 0.630 |
Why?
|
| Mice, Inbred C57BL | 22 | 2024 | 7103 | 0.620 |
Why?
|
| Diet, High-Fat | 1 | 2019 | 247 | 0.600 |
Why?
|
| Scleroderma, Systemic | 4 | 2024 | 165 | 0.590 |
Why?
|
| Macrophages, Alveolar | 4 | 2020 | 71 | 0.590 |
Why?
|
| Smoke | 2 | 2016 | 61 | 0.570 |
Why?
|
| Gene Expression Profiling | 12 | 2024 | 5149 | 0.560 |
Why?
|
| Hermanski-Pudlak Syndrome | 5 | 2022 | 7 | 0.560 |
Why?
|
| Inflammasomes | 2 | 2016 | 174 | 0.560 |
Why?
|
| Receptor-Like Protein Tyrosine Phosphatases, Class 3 | 3 | 2022 | 16 | 0.550 |
Why?
|
| Male | 89 | 2025 | 128397 | 0.540 |
Why?
|
| Epithelial Cells | 9 | 2023 | 1875 | 0.530 |
Why?
|
| Proteomics | 7 | 2024 | 1427 | 0.520 |
Why?
|
| Critical Illness | 1 | 2021 | 740 | 0.520 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 2 | 2024 | 47 | 0.520 |
Why?
|
| Female | 94 | 2025 | 148967 | 0.510 |
Why?
|
| Pollen | 1 | 2015 | 46 | 0.510 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2019 | 540 | 0.510 |
Why?
|
| Aging | 3 | 2024 | 1550 | 0.500 |
Why?
|
| Antiviral Agents | 2 | 2021 | 1253 | 0.490 |
Why?
|
| Bronchoalveolar Lavage Fluid | 11 | 2021 | 269 | 0.490 |
Why?
|
| RNA | 1 | 2020 | 1064 | 0.480 |
Why?
|
| Middle Aged | 69 | 2025 | 90347 | 0.470 |
Why?
|
| Graft Rejection | 6 | 2021 | 847 | 0.470 |
Why?
|
| Phosphatidylinositol 3-Kinases | 4 | 2022 | 1710 | 0.450 |
Why?
|
| Polymorphism, Genetic | 6 | 2017 | 1558 | 0.450 |
Why?
|
| Autophagy | 6 | 2023 | 911 | 0.450 |
Why?
|
| Air Pollutants | 1 | 2015 | 135 | 0.450 |
Why?
|
| MicroRNAs | 5 | 2023 | 2886 | 0.440 |
Why?
|
| Pulmonary Alveoli | 8 | 2022 | 220 | 0.440 |
Why?
|
| Allergens | 1 | 2015 | 252 | 0.440 |
Why?
|
| Pericytes | 1 | 2013 | 91 | 0.430 |
Why?
|
| Aged | 55 | 2024 | 73382 | 0.430 |
Why?
|
| Sirolimus | 4 | 2019 | 831 | 0.430 |
Why?
|
| Lymphangiogenesis | 4 | 2020 | 44 | 0.420 |
Why?
|
| A549 Cells | 3 | 2024 | 128 | 0.420 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 2 | 2017 | 382 | 0.420 |
Why?
|
| Myofibroblasts | 3 | 2024 | 98 | 0.410 |
Why?
|
| Primary Prevention | 1 | 2014 | 233 | 0.410 |
Why?
|
| Smokers | 5 | 2023 | 154 | 0.400 |
Why?
|
| Citrullination | 2 | 2022 | 7 | 0.400 |
Why?
|
| Congresses as Topic | 1 | 2014 | 298 | 0.400 |
Why?
|
| Enzyme Inhibitors | 3 | 2018 | 1946 | 0.390 |
Why?
|
| Hypertension, Pulmonary | 6 | 2020 | 464 | 0.380 |
Why?
|
| Transforming Growth Factor beta | 6 | 2022 | 1109 | 0.380 |
Why?
|
| Mice, Transgenic | 4 | 2022 | 4223 | 0.380 |
Why?
|
| Gene Expression Regulation | 9 | 2022 | 4134 | 0.370 |
Why?
|
| Sequence Analysis, RNA | 4 | 2024 | 676 | 0.360 |
Why?
|
| Virus Internalization | 2 | 2021 | 83 | 0.360 |
Why?
|
| Pattern Recognition, Automated | 1 | 2011 | 120 | 0.360 |
Why?
|
| Respiratory Mucosa | 3 | 2021 | 212 | 0.360 |
Why?
|
| Mitochondria | 6 | 2023 | 1299 | 0.360 |
Why?
|
| Double-Blind Method | 6 | 2022 | 2588 | 0.350 |
Why?
|
| Transcriptome | 4 | 2024 | 1960 | 0.340 |
Why?
|
| Cohort Studies | 18 | 2024 | 9474 | 0.340 |
Why?
|
| Genetic Predisposition to Disease | 8 | 2024 | 5778 | 0.340 |
Why?
|
| Proto-Oncogene Proteins c-akt | 4 | 2022 | 2073 | 0.340 |
Why?
|
| Matrix Metalloproteinase 1 | 2 | 2014 | 51 | 0.340 |
Why?
|
| Trophoblasts | 2 | 2021 | 152 | 0.340 |
Why?
|
| Vesicular Transport Proteins | 3 | 2020 | 149 | 0.330 |
Why?
|
| Severity of Illness Index | 10 | 2023 | 4375 | 0.330 |
Why?
|
| Antibiotics, Antineoplastic | 4 | 2021 | 742 | 0.330 |
Why?
|
| HSP90 Heat-Shock Proteins | 3 | 2016 | 191 | 0.330 |
Why?
|
| Cellular Senescence | 3 | 2021 | 389 | 0.330 |
Why?
|
| Matrix Metalloproteinases, Secreted | 2 | 2023 | 6 | 0.330 |
Why?
|
| Forkhead Transcription Factors | 1 | 2013 | 763 | 0.320 |
Why?
|
| Vascular Endothelial Growth Factor D | 4 | 2017 | 12 | 0.320 |
Why?
|
| Signal Transduction | 13 | 2023 | 12102 | 0.300 |
Why?
|
| Hydroxychloroquine | 2 | 2018 | 31 | 0.300 |
Why?
|
| Autoantibodies | 4 | 2024 | 602 | 0.300 |
Why?
|
| Extracellular Matrix Proteins | 4 | 2022 | 293 | 0.290 |
Why?
|
| Macrophages | 5 | 2023 | 1352 | 0.290 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-3 | 2 | 2018 | 14 | 0.290 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 4 | 2019 | 1280 | 0.290 |
Why?
|
| Immunomodulation | 2 | 2021 | 255 | 0.290 |
Why?
|
| Homeostasis | 6 | 2023 | 926 | 0.290 |
Why?
|
| Lung Neoplasms | 6 | 2023 | 12028 | 0.280 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2019 | 714 | 0.280 |
Why?
|
| Phosphoproteins | 3 | 2018 | 1137 | 0.280 |
Why?
|
| Risk Factors | 16 | 2024 | 17900 | 0.270 |
Why?
|
| Pulmonary Surfactant-Associated Protein D | 2 | 2016 | 13 | 0.270 |
Why?
|
| Adaptor Proteins, Signal Transducing | 4 | 2018 | 1469 | 0.270 |
Why?
|
| Transplant Recipients | 3 | 2019 | 336 | 0.270 |
Why?
|
| Up-Regulation | 6 | 2019 | 2422 | 0.270 |
Why?
|
| Protein Processing, Post-Translational | 4 | 2023 | 809 | 0.260 |
Why?
|
| Adult | 33 | 2025 | 81997 | 0.260 |
Why?
|
| Gene Expression | 2 | 2020 | 3642 | 0.250 |
Why?
|
| In Vitro Techniques | 2 | 2021 | 1710 | 0.250 |
Why?
|
| Genetic Testing | 3 | 2021 | 1697 | 0.240 |
Why?
|
| Inflammation | 5 | 2021 | 2518 | 0.240 |
Why?
|
| Gene Regulatory Networks | 2 | 2022 | 680 | 0.240 |
Why?
|
| Methylmalonic Acid | 1 | 2024 | 17 | 0.240 |
Why?
|
| Chronic Disease | 5 | 2021 | 1828 | 0.240 |
Why?
|
| Kruppel-Like Transcription Factors | 2 | 2024 | 277 | 0.240 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 6 | 2020 | 1525 | 0.230 |
Why?
|
| Bronchiolitis Obliterans | 2 | 2017 | 94 | 0.230 |
Why?
|
| Cells, Cultured | 8 | 2022 | 5698 | 0.230 |
Why?
|
| Blood Proteins | 3 | 2023 | 299 | 0.230 |
Why?
|
| Galectin 3 | 2 | 2016 | 131 | 0.230 |
Why?
|
| Disease Models, Animal | 9 | 2024 | 7383 | 0.230 |
Why?
|
| Prognosis | 11 | 2023 | 22481 | 0.230 |
Why?
|
| Antibodies, Viral | 2 | 2023 | 1301 | 0.230 |
Why?
|
| Promoter Regions, Genetic | 7 | 2019 | 3215 | 0.220 |
Why?
|
| Telomerase | 4 | 2020 | 547 | 0.220 |
Why?
|
| Niacin | 1 | 2023 | 58 | 0.220 |
Why?
|
| Citrulline | 2 | 2016 | 113 | 0.220 |
Why?
|
| Stem Cells | 3 | 2021 | 1217 | 0.220 |
Why?
|
| Immunoglobulin A | 2 | 2023 | 271 | 0.210 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2024 | 344 | 0.210 |
Why?
|
| Intensive Care Units | 2 | 2021 | 738 | 0.210 |
Why?
|
| Protein Kinases | 2 | 2018 | 903 | 0.210 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 5 | 2019 | 2474 | 0.210 |
Why?
|
| Gene Silencing | 3 | 2021 | 827 | 0.210 |
Why?
|
| Synovial Membrane | 1 | 2022 | 47 | 0.210 |
Why?
|
| Anti-Citrullinated Protein Antibodies | 1 | 2022 | 4 | 0.200 |
Why?
|
| Sarcoidosis | 1 | 2023 | 113 | 0.200 |
Why?
|
| Reperfusion Injury | 1 | 2023 | 151 | 0.200 |
Why?
|
| Pseudomonas Infections | 1 | 2023 | 166 | 0.200 |
Why?
|
| Interleukin-1beta | 2 | 2016 | 295 | 0.200 |
Why?
|
| Hospital Mortality | 2 | 2021 | 1234 | 0.200 |
Why?
|
| United States | 13 | 2024 | 15855 | 0.200 |
Why?
|
| Case-Control Studies | 10 | 2021 | 6237 | 0.200 |
Why?
|
| Mammals | 2 | 2022 | 368 | 0.200 |
Why?
|
| Genome-Wide Association Study | 3 | 2020 | 2351 | 0.190 |
Why?
|
| Elastic Tissue | 1 | 2021 | 35 | 0.190 |
Why?
|
| Chemokine CXCL10 | 3 | 2022 | 106 | 0.190 |
Why?
|
| Adenosine Monophosphate | 1 | 2021 | 76 | 0.190 |
Why?
|
| Adaptor Protein Complex 3 | 1 | 2021 | 2 | 0.190 |
Why?
|
| Adaptor Protein Complex beta Subunits | 1 | 2021 | 2 | 0.190 |
Why?
|
| Veterans | 2 | 2023 | 1740 | 0.190 |
Why?
|
| Respiratory System Abnormalities | 1 | 2021 | 42 | 0.190 |
Why?
|
| TOR Serine-Threonine Kinases | 4 | 2021 | 1564 | 0.190 |
Why?
|
| Cluster Analysis | 2 | 2022 | 1076 | 0.190 |
Why?
|
| Machine Learning | 1 | 2024 | 363 | 0.190 |
Why?
|
| Sp1 Transcription Factor | 1 | 2022 | 193 | 0.190 |
Why?
|
| Desmoplakins | 1 | 2020 | 17 | 0.190 |
Why?
|
| Bronchitis, Chronic | 1 | 2021 | 30 | 0.190 |
Why?
|
| Airway Resistance | 1 | 2020 | 43 | 0.180 |
Why?
|
| Cell Proliferation | 5 | 2024 | 7237 | 0.180 |
Why?
|
| Viral Load | 1 | 2023 | 485 | 0.180 |
Why?
|
| Respiration, Artificial | 2 | 2022 | 581 | 0.180 |
Why?
|
| Primary Cell Culture | 1 | 2021 | 200 | 0.180 |
Why?
|
| Alanine | 1 | 2021 | 247 | 0.180 |
Why?
|
| Collagen | 2 | 2022 | 726 | 0.180 |
Why?
|
| Antirheumatic Agents | 2 | 2021 | 230 | 0.180 |
Why?
|
| Prospective Studies | 9 | 2022 | 13417 | 0.180 |
Why?
|
| Acute Lung Injury | 1 | 2021 | 92 | 0.180 |
Why?
|
| Cell Differentiation | 4 | 2024 | 4117 | 0.180 |
Why?
|
| Lymphatic Vessels | 3 | 2019 | 138 | 0.180 |
Why?
|
| Spirometry | 5 | 2021 | 153 | 0.180 |
Why?
|
| Administration, Inhalation | 2 | 2019 | 300 | 0.180 |
Why?
|
| Genetic Markers | 4 | 2019 | 1075 | 0.180 |
Why?
|
| Vascular Diseases | 1 | 2022 | 235 | 0.180 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 2 | 2021 | 205 | 0.170 |
Why?
|
| Celecoxib | 1 | 2020 | 198 | 0.170 |
Why?
|
| CD36 Antigens | 1 | 2019 | 51 | 0.170 |
Why?
|
| Hexosaminidases | 1 | 2019 | 10 | 0.170 |
Why?
|
| Syntenins | 1 | 2019 | 5 | 0.170 |
Why?
|
| Smad7 Protein | 1 | 2019 | 13 | 0.170 |
Why?
|
| beta Catenin | 2 | 2023 | 683 | 0.170 |
Why?
|
| Genomics | 2 | 2024 | 2836 | 0.170 |
Why?
|
| Immunosuppressive Agents | 4 | 2023 | 1431 | 0.170 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2020 | 198 | 0.170 |
Why?
|
| Follow-Up Studies | 11 | 2024 | 15212 | 0.170 |
Why?
|
| Treatment Outcome | 11 | 2022 | 33741 | 0.170 |
Why?
|
| Extracellular Vesicles | 1 | 2021 | 134 | 0.160 |
Why?
|
| Endostatins | 1 | 2019 | 48 | 0.160 |
Why?
|
| Prevalence | 8 | 2024 | 3402 | 0.160 |
Why?
|
| Polyamines | 1 | 2019 | 80 | 0.160 |
Why?
|
| Insulin Resistance | 1 | 2025 | 732 | 0.160 |
Why?
|
| Forkhead Box Protein O3 | 1 | 2019 | 108 | 0.160 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2016 | 1689 | 0.160 |
Why?
|
| DNA | 2 | 2018 | 3051 | 0.160 |
Why?
|
| Phenotype | 5 | 2022 | 6516 | 0.160 |
Why?
|
| Myositis | 2 | 2018 | 87 | 0.160 |
Why?
|
| Precision Medicine | 2 | 2024 | 1208 | 0.160 |
Why?
|
| Immunohistochemistry | 4 | 2020 | 7665 | 0.160 |
Why?
|
| Collagen Type III | 1 | 2018 | 19 | 0.160 |
Why?
|
| Tacrolimus | 1 | 2020 | 347 | 0.160 |
Why?
|
| Immunologic Factors | 2 | 2024 | 672 | 0.160 |
Why?
|
| Transcription Factor RelA | 1 | 2019 | 184 | 0.160 |
Why?
|
| Host-Pathogen Interactions | 1 | 2021 | 304 | 0.160 |
Why?
|
| Total Lung Capacity | 3 | 2015 | 18 | 0.160 |
Why?
|
| Acetyl-CoA Carboxylase | 1 | 2018 | 52 | 0.160 |
Why?
|
| Triglycerides | 1 | 2021 | 612 | 0.150 |
Why?
|
| ROC Curve | 3 | 2017 | 1250 | 0.150 |
Why?
|
| Laminin | 1 | 2018 | 209 | 0.150 |
Why?
|
| Carboxyhemoglobin | 1 | 2017 | 7 | 0.150 |
Why?
|
| Infusions, Intravenous | 1 | 2021 | 1437 | 0.150 |
Why?
|
| Disease Susceptibility | 2 | 2021 | 550 | 0.150 |
Why?
|
| Mice, SCID | 2 | 2019 | 1825 | 0.150 |
Why?
|
| Longitudinal Studies | 6 | 2020 | 2057 | 0.150 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2019 | 350 | 0.150 |
Why?
|
| Connectome | 1 | 2019 | 113 | 0.150 |
Why?
|
| Tissue Donors | 3 | 2017 | 815 | 0.150 |
Why?
|
| Cystic Fibrosis | 1 | 2020 | 294 | 0.150 |
Why?
|
| Myocytes, Smooth Muscle | 2 | 2016 | 183 | 0.150 |
Why?
|
| Gain of Function Mutation | 1 | 2018 | 133 | 0.150 |
Why?
|
| rho-Associated Kinases | 1 | 2018 | 80 | 0.150 |
Why?
|
| Fibrinogen | 1 | 2018 | 212 | 0.150 |
Why?
|
| Treatment Failure | 1 | 2021 | 1428 | 0.150 |
Why?
|
| Metabolic Syndrome | 1 | 2021 | 368 | 0.140 |
Why?
|
| Respiratory Tract Diseases | 1 | 2018 | 111 | 0.140 |
Why?
|
| Rituximab | 2 | 2024 | 1593 | 0.140 |
Why?
|
| Respiratory Tract Infections | 1 | 2021 | 408 | 0.140 |
Why?
|
| Tuberous Sclerosis | 2 | 2019 | 145 | 0.140 |
Why?
|
| Retrospective Studies | 18 | 2024 | 39832 | 0.140 |
Why?
|
| Interleukin-8 | 2 | 2022 | 531 | 0.140 |
Why?
|
| Syk Kinase | 1 | 2017 | 65 | 0.140 |
Why?
|
| Histocompatibility | 1 | 2017 | 183 | 0.140 |
Why?
|
| Protein-Arginine Deiminases | 3 | 2023 | 7 | 0.140 |
Why?
|
| Parenchymal Tissue | 1 | 2016 | 9 | 0.140 |
Why?
|
| Aged, 80 and over | 12 | 2021 | 31008 | 0.140 |
Why?
|
| Apoptosis | 5 | 2019 | 7754 | 0.140 |
Why?
|
| Isoantibodies | 1 | 2017 | 120 | 0.140 |
Why?
|
| Instillation, Drug | 1 | 2016 | 15 | 0.140 |
Why?
|
| Protein Unfolding | 1 | 2016 | 11 | 0.140 |
Why?
|
| Immunoproteins | 1 | 2016 | 2 | 0.140 |
Why?
|
| Photopheresis | 1 | 2017 | 79 | 0.140 |
Why?
|
| Alemtuzumab | 1 | 2017 | 213 | 0.140 |
Why?
|
| Biomedical Research | 1 | 2024 | 799 | 0.140 |
Why?
|
| Transcriptional Activation | 1 | 2020 | 1111 | 0.140 |
Why?
|
| Solitary Pulmonary Nodule | 1 | 2018 | 125 | 0.140 |
Why?
|
| Thorax | 1 | 2018 | 232 | 0.140 |
Why?
|
| Allografts | 4 | 2021 | 686 | 0.140 |
Why?
|
| Absorptiometry, Photon | 1 | 2017 | 235 | 0.130 |
Why?
|
| Risk Assessment | 6 | 2017 | 6768 | 0.130 |
Why?
|
| Taste | 1 | 2016 | 54 | 0.130 |
Why?
|
| Osteopontin | 1 | 2016 | 145 | 0.130 |
Why?
|
| Pneumonia | 1 | 2022 | 796 | 0.130 |
Why?
|
| Interleukin-18 | 1 | 2016 | 91 | 0.130 |
Why?
|
| Tissue Banks | 1 | 2016 | 51 | 0.130 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2022 | 4961 | 0.130 |
Why?
|
| Bronchoalveolar Lavage | 2 | 2013 | 55 | 0.130 |
Why?
|
| Cell Survival | 2 | 2020 | 3063 | 0.130 |
Why?
|
| Magnoliopsida | 1 | 2015 | 10 | 0.130 |
Why?
|
| Embolism, Fat | 1 | 2015 | 8 | 0.130 |
Why?
|
| Vascular Endothelial Growth Factor C | 1 | 2015 | 29 | 0.130 |
Why?
|
| Urbanization | 1 | 2015 | 7 | 0.130 |
Why?
|
| Family | 1 | 2020 | 784 | 0.130 |
Why?
|
| Mice, Knockout | 4 | 2021 | 5731 | 0.130 |
Why?
|
| Cell Movement | 3 | 2022 | 2472 | 0.130 |
Why?
|
| Peptide Fragments | 1 | 2021 | 1309 | 0.130 |
Why?
|
| Proportional Hazards Models | 6 | 2022 | 5102 | 0.130 |
Why?
|
| Sepsis | 1 | 2021 | 686 | 0.130 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2023 | 1655 | 0.130 |
Why?
|
| Recombinant Proteins | 1 | 2021 | 3028 | 0.130 |
Why?
|
| B-Cell Activating Factor | 1 | 2015 | 26 | 0.130 |
Why?
|
| Sulfur | 1 | 2015 | 17 | 0.130 |
Why?
|
| Cities | 1 | 2015 | 57 | 0.130 |
Why?
|
| Cell Line | 6 | 2021 | 5339 | 0.130 |
Why?
|
| Cigarette Smoking | 1 | 2016 | 102 | 0.130 |
Why?
|
| Iron-Sulfur Proteins | 1 | 2015 | 22 | 0.130 |
Why?
|
| Referral and Consultation | 1 | 2021 | 931 | 0.130 |
Why?
|
| Microbiota | 1 | 2021 | 547 | 0.130 |
Why?
|
| Lymphoid Tissue | 1 | 2015 | 102 | 0.120 |
Why?
|
| Regression Analysis | 4 | 2024 | 1571 | 0.120 |
Why?
|
| Transplants | 1 | 2015 | 50 | 0.120 |
Why?
|
| Carcinoma, Bronchogenic | 1 | 2015 | 35 | 0.120 |
Why?
|
| Glucose | 1 | 2021 | 1220 | 0.120 |
Why?
|
| Biological Assay | 1 | 2016 | 178 | 0.120 |
Why?
|
| Mexico | 1 | 2015 | 275 | 0.120 |
Why?
|
| Phospholipases A2 | 1 | 2014 | 45 | 0.120 |
Why?
|
| DNA Damage | 2 | 2013 | 1988 | 0.120 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2017 | 381 | 0.120 |
Why?
|
| Cysteine-Rich Protein 61 | 1 | 2014 | 8 | 0.120 |
Why?
|
| Age Factors | 4 | 2019 | 5465 | 0.120 |
Why?
|
| Mononuclear Phagocyte System | 1 | 2014 | 11 | 0.120 |
Why?
|
| Matrix Metalloproteinase 8 | 1 | 2014 | 16 | 0.120 |
Why?
|
| Lipids | 1 | 2018 | 654 | 0.120 |
Why?
|
| Radiation Injuries, Experimental | 1 | 2014 | 80 | 0.120 |
Why?
|
| NF-kappa B | 1 | 2021 | 1564 | 0.120 |
Why?
|
| Carrier Proteins | 2 | 2013 | 2100 | 0.120 |
Why?
|
| Adaptive Immunity | 1 | 2015 | 151 | 0.120 |
Why?
|
| HLA Antigens | 1 | 2017 | 594 | 0.120 |
Why?
|
| Sensitivity and Specificity | 7 | 2019 | 5171 | 0.120 |
Why?
|
| Rare Diseases | 1 | 2017 | 360 | 0.120 |
Why?
|
| Chemokines | 1 | 2015 | 290 | 0.110 |
Why?
|
| Tumor Suppressor Proteins | 3 | 2017 | 1902 | 0.110 |
Why?
|
| Temperature | 1 | 2015 | 538 | 0.110 |
Why?
|
| Hydroxyproline | 1 | 2013 | 9 | 0.110 |
Why?
|
| Bronchodilator Agents | 1 | 2016 | 225 | 0.110 |
Why?
|
| Seasons | 1 | 2015 | 338 | 0.110 |
Why?
|
| Epitopes | 1 | 2016 | 707 | 0.110 |
Why?
|
| Drug Approval | 1 | 2015 | 174 | 0.110 |
Why?
|
| Cell Nucleus | 1 | 2019 | 1712 | 0.110 |
Why?
|
| Area Under Curve | 1 | 2015 | 729 | 0.110 |
Why?
|
| United States Food and Drug Administration | 1 | 2015 | 324 | 0.110 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2013 | 57 | 0.110 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2024 | 4645 | 0.110 |
Why?
|
| Herpesvirus 4, Human | 1 | 2017 | 960 | 0.110 |
Why?
|
| Circadian Rhythm | 1 | 2015 | 332 | 0.110 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2017 | 480 | 0.110 |
Why?
|
| Bone Marrow | 3 | 2018 | 2438 | 0.110 |
Why?
|
| Transplantation | 1 | 2013 | 57 | 0.110 |
Why?
|
| Protein Structure, Tertiary | 1 | 2016 | 1472 | 0.110 |
Why?
|
| Sex Factors | 2 | 2015 | 2184 | 0.110 |
Why?
|
| Linear Models | 4 | 2019 | 1097 | 0.110 |
Why?
|
| Asthma | 1 | 2021 | 895 | 0.110 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2014 | 303 | 0.110 |
Why?
|
| Everolimus | 1 | 2015 | 436 | 0.110 |
Why?
|
| Adipocytes | 1 | 2014 | 298 | 0.100 |
Why?
|
| Logistic Models | 5 | 2019 | 3448 | 0.100 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2015 | 500 | 0.100 |
Why?
|
| Cause of Death | 1 | 2016 | 788 | 0.100 |
Why?
|
| Nuclear Receptor Subfamily 1, Group F, Member 1 | 1 | 2012 | 30 | 0.100 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2016 | 485 | 0.100 |
Why?
|
| Radiation Pneumonitis | 1 | 2014 | 313 | 0.100 |
Why?
|
| Caveolin 1 | 1 | 2013 | 202 | 0.100 |
Why?
|
| Mass Screening | 1 | 2021 | 1549 | 0.100 |
Why?
|
| Genetic Variation | 1 | 2020 | 2165 | 0.100 |
Why?
|
| Hypoxia | 1 | 2015 | 472 | 0.100 |
Why?
|
| DNA, Mitochondrial | 1 | 2013 | 315 | 0.100 |
Why?
|
| Autoantigens | 1 | 2013 | 248 | 0.100 |
Why?
|
| Tissue Array Analysis | 1 | 2013 | 757 | 0.100 |
Why?
|
| Patient Readmission | 1 | 2016 | 572 | 0.100 |
Why?
|
| Pancytopenia | 1 | 2012 | 119 | 0.100 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2017 | 864 | 0.100 |
Why?
|
| Hospitalization | 1 | 2021 | 2168 | 0.100 |
Why?
|
| Antibodies | 1 | 2014 | 809 | 0.090 |
Why?
|
| Postoperative Complications | 2 | 2017 | 5676 | 0.090 |
Why?
|
| Exercise Tolerance | 1 | 2012 | 106 | 0.090 |
Why?
|
| Neoplasm Invasiveness | 1 | 2019 | 4048 | 0.090 |
Why?
|
| HLA-DR Antigens | 1 | 2011 | 184 | 0.090 |
Why?
|
| Young Adult | 6 | 2024 | 22225 | 0.090 |
Why?
|
| Thoracic Surgery, Video-Assisted | 1 | 2012 | 211 | 0.090 |
Why?
|
| Reproducibility of Results | 4 | 2017 | 6193 | 0.090 |
Why?
|
| Telomere Shortening | 2 | 2024 | 56 | 0.090 |
Why?
|
| Diagnosis, Differential | 3 | 2016 | 4831 | 0.090 |
Why?
|
| Cyclooxygenase 2 | 1 | 2012 | 495 | 0.090 |
Why?
|
| Organ Specificity | 2 | 2021 | 737 | 0.080 |
Why?
|
| Antibodies, Antinuclear | 1 | 2009 | 50 | 0.080 |
Why?
|
| Survival Rate | 6 | 2019 | 12527 | 0.080 |
Why?
|
| Incidence | 5 | 2019 | 5828 | 0.080 |
Why?
|
| B-Lymphocytes | 1 | 2015 | 1424 | 0.080 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2009 | 101 | 0.080 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 2 | 2022 | 66 | 0.080 |
Why?
|
| Iceland | 2 | 2019 | 14 | 0.080 |
Why?
|
| Syndecan-1 | 1 | 2008 | 52 | 0.080 |
Why?
|
| Genotype | 4 | 2018 | 4255 | 0.080 |
Why?
|
| Radiographic Image Enhancement | 1 | 2011 | 410 | 0.080 |
Why?
|
| Clinical Enzyme Tests | 1 | 2008 | 25 | 0.080 |
Why?
|
| Biopsy | 3 | 2015 | 3483 | 0.080 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2017 | 2453 | 0.080 |
Why?
|
| Interleukin-17 | 1 | 2010 | 255 | 0.080 |
Why?
|
| Odds Ratio | 3 | 2018 | 2311 | 0.070 |
Why?
|
| Biopsy, Needle | 1 | 2012 | 1379 | 0.070 |
Why?
|
| Time Factors | 5 | 2021 | 13021 | 0.070 |
Why?
|
| Radiotherapy | 1 | 2014 | 1857 | 0.070 |
Why?
|
| Protein Binding | 3 | 2020 | 3485 | 0.070 |
Why?
|
| RNA, Long Noncoding | 1 | 2013 | 618 | 0.070 |
Why?
|
| Radiography, Thoracic | 1 | 2009 | 477 | 0.070 |
Why?
|
| Extracellular Matrix | 2 | 2022 | 523 | 0.070 |
Why?
|
| Oxidative Stress | 2 | 2014 | 1149 | 0.070 |
Why?
|
| Enzyme Activation | 2 | 2024 | 1811 | 0.070 |
Why?
|
| Methotrexate | 2 | 2021 | 1025 | 0.070 |
Why?
|
| RNA Stability | 1 | 2007 | 134 | 0.070 |
Why?
|
| Neovascularization, Pathologic | 1 | 2013 | 1585 | 0.070 |
Why?
|
| Pulmonary Artery | 2 | 2021 | 521 | 0.060 |
Why?
|
| Mutation | 6 | 2017 | 15911 | 0.060 |
Why?
|
| Survival Analysis | 2 | 2019 | 9290 | 0.060 |
Why?
|
| Attitude of Health Personnel | 1 | 2012 | 900 | 0.060 |
Why?
|
| Liver | 1 | 2015 | 3089 | 0.060 |
Why?
|
| Microarray Analysis | 1 | 2006 | 397 | 0.060 |
Why?
|
| Lakes | 1 | 2024 | 3 | 0.060 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 1 | 2024 | 115 | 0.060 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2012 | 823 | 0.060 |
Why?
|
| Proteins | 2 | 2023 | 2043 | 0.060 |
Why?
|
| Stress Fibers | 1 | 2023 | 15 | 0.060 |
Why?
|
| Acetate-CoA Ligase | 1 | 2023 | 8 | 0.060 |
Why?
|
| Interferon-gamma | 2 | 2023 | 1180 | 0.060 |
Why?
|
| Acetyl Coenzyme A | 1 | 2023 | 22 | 0.060 |
Why?
|
| Professional Practice Gaps | 1 | 2023 | 15 | 0.050 |
Why?
|
| Surveys and Questionnaires | 3 | 2021 | 5923 | 0.050 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2012 | 1301 | 0.050 |
Why?
|
| Chaperonin Containing TCP-1 | 1 | 2023 | 18 | 0.050 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2019 | 9041 | 0.050 |
Why?
|
| Monocytes | 2 | 2023 | 790 | 0.050 |
Why?
|
| Fenbendazole | 1 | 2022 | 7 | 0.050 |
Why?
|
| RNA, Small Interfering | 2 | 2019 | 2196 | 0.050 |
Why?
|
| Thyroid Hormones | 1 | 2023 | 112 | 0.050 |
Why?
|
| Plasma Exchange | 1 | 2024 | 104 | 0.050 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2024 | 191 | 0.050 |
Why?
|
| Pedigree | 2 | 2021 | 2042 | 0.050 |
Why?
|
| Nonmuscle Myosin Type IIB | 1 | 2022 | 3 | 0.050 |
Why?
|
| Albinism | 1 | 2022 | 17 | 0.050 |
Why?
|
| Receptors, Angiotensin | 1 | 2022 | 46 | 0.050 |
Why?
|
| Activating Transcription Factor 4 | 1 | 2022 | 80 | 0.050 |
Why?
|
| Immunoglobulin M | 1 | 2023 | 359 | 0.050 |
Why?
|
| Chemokine CCL5 | 1 | 2022 | 76 | 0.050 |
Why?
|
| Protein Isoforms | 2 | 2016 | 848 | 0.050 |
Why?
|
| Lymphocyte Activation | 1 | 2007 | 1723 | 0.050 |
Why?
|
| Losartan | 1 | 2022 | 44 | 0.050 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2022 | 104 | 0.050 |
Why?
|
| Mass Spectrometry | 2 | 2016 | 722 | 0.050 |
Why?
|
| Hemiterpenes | 1 | 2001 | 6 | 0.050 |
Why?
|
| Hemorrhagic Disorders | 1 | 2022 | 52 | 0.050 |
Why?
|
| Mycophenolic Acid | 1 | 2023 | 153 | 0.050 |
Why?
|
| Reactive Oxygen Species | 2 | 2018 | 1006 | 0.050 |
Why?
|
| Niacinamide | 1 | 2023 | 428 | 0.050 |
Why?
|
| Regeneration | 1 | 2024 | 283 | 0.050 |
Why?
|
| RNA, Messenger | 2 | 2014 | 6398 | 0.050 |
Why?
|
| Neutrophils | 2 | 2021 | 873 | 0.050 |
Why?
|
| Fatal Outcome | 2 | 2015 | 824 | 0.050 |
Why?
|
| Multivariate Analysis | 2 | 2019 | 4328 | 0.050 |
Why?
|
| Acute Disease | 2 | 2018 | 2496 | 0.050 |
Why?
|
| Ribotyping | 1 | 2021 | 52 | 0.050 |
Why?
|
| Molecular Epidemiology | 1 | 2022 | 247 | 0.050 |
Why?
|
| Registries | 2 | 2020 | 2209 | 0.050 |
Why?
|
| Cathepsin L | 1 | 2021 | 31 | 0.050 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2021 | 2359 | 0.050 |
Why?
|
| Capillaries | 1 | 2021 | 98 | 0.050 |
Why?
|
| Unfolded Protein Response | 1 | 2021 | 112 | 0.050 |
Why?
|
| Paracrine Communication | 1 | 2021 | 128 | 0.050 |
Why?
|
| Microfilament Proteins | 1 | 2023 | 494 | 0.050 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2015 | 695 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2019 | 1579 | 0.050 |
Why?
|
| Ubiquitination | 1 | 2023 | 579 | 0.050 |
Why?
|
| Lung Diseases, Fungal | 1 | 2021 | 132 | 0.050 |
Why?
|
| Microcirculation | 1 | 2021 | 190 | 0.050 |
Why?
|
| Cell Cycle Proteins | 2 | 2022 | 2115 | 0.040 |
Why?
|
| Dysbiosis | 1 | 2021 | 152 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2021 | 179 | 0.040 |
Why?
|
| Respiratory System | 1 | 2021 | 129 | 0.040 |
Why?
|
| TATA Box Binding Protein-Like Proteins | 1 | 2019 | 1 | 0.040 |
Why?
|
| Cell Polarity | 1 | 2021 | 212 | 0.040 |
Why?
|
| Activins | 1 | 2020 | 94 | 0.040 |
Why?
|
| Phagocytosis | 1 | 2021 | 292 | 0.040 |
Why?
|
| NFATC Transcription Factors | 1 | 2020 | 96 | 0.040 |
Why?
|
| Respiration Disorders | 1 | 2020 | 48 | 0.040 |
Why?
|
| Early Diagnosis | 1 | 2021 | 314 | 0.040 |
Why?
|
| Semaphorins | 1 | 2019 | 37 | 0.040 |
Why?
|
| src-Family Kinases | 1 | 2022 | 487 | 0.040 |
Why?
|
| beta Karyopherins | 1 | 2019 | 34 | 0.040 |
Why?
|
| Contraindications | 1 | 2000 | 154 | 0.040 |
Why?
|
| Serine Endopeptidases | 1 | 2021 | 275 | 0.040 |
Why?
|
| Demography | 1 | 2021 | 433 | 0.040 |
Why?
|
| Oxidation-Reduction | 1 | 2021 | 704 | 0.040 |
Why?
|
| Inflammation Mediators | 1 | 2022 | 402 | 0.040 |
Why?
|
| Extracellular Space | 1 | 2019 | 148 | 0.040 |
Why?
|
| Adolescent | 2 | 2017 | 32743 | 0.040 |
Why?
|
| Maleimides | 1 | 2019 | 23 | 0.040 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2022 | 770 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2019 | 5071 | 0.040 |
Why?
|
| Zebrafish | 1 | 2022 | 457 | 0.040 |
Why?
|
| Pulmonary Veins | 1 | 2021 | 181 | 0.040 |
Why?
|
| Nutrition Surveys | 1 | 2021 | 317 | 0.040 |
Why?
|
| Radiologists | 1 | 2021 | 178 | 0.040 |
Why?
|
| Immunity | 1 | 2021 | 355 | 0.040 |
Why?
|
| Biological Transport | 1 | 2020 | 627 | 0.040 |
Why?
|
| Skin | 1 | 2024 | 1274 | 0.040 |
Why?
|
| Lipopolysaccharides | 1 | 2021 | 589 | 0.040 |
Why?
|
| Symptom Assessment | 1 | 2021 | 272 | 0.040 |
Why?
|
| Trans-Activators | 2 | 2015 | 1624 | 0.040 |
Why?
|
| Calcium-Binding Proteins | 1 | 2021 | 545 | 0.040 |
Why?
|
| Transcription, Genetic | 1 | 2007 | 3341 | 0.040 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2019 | 158 | 0.040 |
Why?
|
| Airway Remodeling | 1 | 2018 | 28 | 0.040 |
Why?
|
| Smad2 Protein | 1 | 2018 | 89 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2022 | 1129 | 0.040 |
Why?
|
| Stromal Cells | 1 | 2022 | 826 | 0.040 |
Why?
|
| Genes | 1 | 2019 | 607 | 0.040 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2021 | 592 | 0.040 |
Why?
|
| Species Specificity | 1 | 2019 | 794 | 0.040 |
Why?
|
| Hospitals, Veterans | 1 | 2020 | 371 | 0.040 |
Why?
|
| Oxygen | 1 | 2023 | 792 | 0.040 |
Why?
|
| Macrophage Activation | 1 | 2018 | 151 | 0.040 |
Why?
|
| Cell Separation | 1 | 2020 | 610 | 0.040 |
Why?
|
| Protein Stability | 1 | 2019 | 377 | 0.040 |
Why?
|
| Microvessels | 1 | 2019 | 145 | 0.040 |
Why?
|
| Green Fluorescent Proteins | 1 | 2020 | 693 | 0.040 |
Why?
|
| Oxidative Phosphorylation | 1 | 2019 | 271 | 0.040 |
Why?
|
| Consensus | 1 | 2023 | 1105 | 0.040 |
Why?
|
| Alleles | 2 | 2017 | 2602 | 0.040 |
Why?
|
| Smad3 Protein | 1 | 2018 | 123 | 0.040 |
Why?
|
| Databases, Genetic | 1 | 2021 | 757 | 0.040 |
Why?
|
| Mice, Inbred Strains | 1 | 2018 | 563 | 0.040 |
Why?
|
| Systems Biology | 1 | 2018 | 115 | 0.040 |
Why?
|
| Biomarkers, Tumor | 1 | 2017 | 10706 | 0.040 |
Why?
|
| Virus Replication | 1 | 2021 | 784 | 0.040 |
Why?
|
| Medicare | 1 | 2023 | 926 | 0.040 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2017 | 78 | 0.040 |
Why?
|
| Software | 1 | 2024 | 1356 | 0.040 |
Why?
|
| Genetic Loci | 1 | 2019 | 501 | 0.040 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2023 | 1002 | 0.040 |
Why?
|
| Pyridines | 1 | 2024 | 1311 | 0.040 |
Why?
|
| Ligands | 1 | 2019 | 1016 | 0.040 |
Why?
|
| Walk Test | 1 | 2017 | 43 | 0.040 |
Why?
|
| Boston | 1 | 2017 | 133 | 0.040 |
Why?
|
| Academic Medical Centers | 1 | 2020 | 681 | 0.040 |
Why?
|
| Genes, Reporter | 1 | 2019 | 820 | 0.040 |
Why?
|
| Immunity, Innate | 1 | 2021 | 700 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2022 | 700 | 0.030 |
Why?
|
| Muscle Relaxation | 1 | 2016 | 22 | 0.030 |
Why?
|
| Cell Culture Techniques | 1 | 2019 | 574 | 0.030 |
Why?
|
| Massachusetts | 1 | 2016 | 145 | 0.030 |
Why?
|
| Phagocytes | 1 | 2016 | 47 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 2020 | 799 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 2018 | 352 | 0.030 |
Why?
|
| Chemokine CCL2 | 1 | 2017 | 198 | 0.030 |
Why?
|
| LDL-Receptor Related Proteins | 1 | 2015 | 17 | 0.030 |
Why?
|
| Mucositis | 1 | 2017 | 149 | 0.030 |
Why?
|
| Headache | 1 | 2017 | 175 | 0.030 |
Why?
|
| Receptors, Cell Surface | 1 | 2019 | 904 | 0.030 |
Why?
|
| Benzylamines | 1 | 2015 | 98 | 0.030 |
Why?
|
| Hydrolases | 1 | 2016 | 132 | 0.030 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2016 | 141 | 0.030 |
Why?
|
| Glucocorticoids | 1 | 2019 | 618 | 0.030 |
Why?
|
| Histocompatibility Testing | 1 | 2017 | 487 | 0.030 |
Why?
|
| Muscle Contraction | 1 | 2016 | 229 | 0.030 |
Why?
|
| Down-Regulation | 2 | 2014 | 2091 | 0.030 |
Why?
|
| Energy Metabolism | 1 | 2021 | 998 | 0.030 |
Why?
|
| Serpin E2 | 1 | 2014 | 2 | 0.030 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2021 | 1503 | 0.030 |
Why?
|
| Blood Cell Count | 1 | 2015 | 233 | 0.030 |
Why?
|
| Apolipoproteins E | 1 | 2015 | 220 | 0.030 |
Why?
|
| Liver Function Tests | 1 | 2015 | 185 | 0.030 |
Why?
|
| Molecular Weight | 1 | 2015 | 721 | 0.030 |
Why?
|
| Gastrointestinal Diseases | 1 | 2000 | 607 | 0.030 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2015 | 126 | 0.030 |
Why?
|
| Observer Variation | 1 | 2017 | 709 | 0.030 |
Why?
|
| Repressor Proteins | 1 | 2022 | 1717 | 0.030 |
Why?
|
| Benzoates | 1 | 2015 | 128 | 0.030 |
Why?
|
| Computational Biology | 1 | 2021 | 1293 | 0.030 |
Why?
|
| Angiomyolipoma | 1 | 2014 | 30 | 0.030 |
Why?
|
| Length of Stay | 1 | 2022 | 2007 | 0.030 |
Why?
|
| Fibrinolysin | 1 | 2014 | 25 | 0.030 |
Why?
|
| Integrin alpha Chains | 1 | 2014 | 23 | 0.030 |
Why?
|
| NIH 3T3 Cells | 1 | 2014 | 255 | 0.030 |
Why?
|
| Kidney Diseases | 1 | 2000 | 694 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2016 | 667 | 0.030 |
Why?
|
| Epitope Mapping | 1 | 2014 | 110 | 0.030 |
Why?
|
| Calcium Signaling | 1 | 2016 | 282 | 0.030 |
Why?
|
| Membrane Transport Proteins | 1 | 2015 | 246 | 0.030 |
Why?
|
| Mechanotransduction, Cellular | 1 | 2014 | 87 | 0.030 |
Why?
|
| Neutrophil Infiltration | 1 | 2014 | 108 | 0.030 |
Why?
|
| Radiation, Ionizing | 1 | 2014 | 190 | 0.030 |
Why?
|
| Antibody Specificity | 1 | 2014 | 337 | 0.030 |
Why?
|
| Gene Knockout Techniques | 1 | 2014 | 269 | 0.030 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2015 | 329 | 0.030 |
Why?
|
| Heart Diseases | 1 | 2000 | 723 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2015 | 749 | 0.030 |
Why?
|
| Galectins | 1 | 2014 | 73 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2020 | 3045 | 0.030 |
Why?
|
| Mixed Connective Tissue Disease | 1 | 2013 | 3 | 0.030 |
Why?
|
| Germ-Line Mutation | 1 | 2019 | 1101 | 0.030 |
Why?
|
| Adipose Tissue | 1 | 2018 | 717 | 0.030 |
Why?
|
| Mucin-1 | 1 | 2014 | 158 | 0.030 |
Why?
|
| Diarrhea | 1 | 2017 | 716 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2018 | 2212 | 0.030 |
Why?
|
| China | 1 | 2015 | 635 | 0.030 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2014 | 751 | 0.030 |
Why?
|
| Pandemics | 1 | 2022 | 1610 | 0.030 |
Why?
|
| Arginine | 1 | 2016 | 508 | 0.030 |
Why?
|
| Remission Induction | 1 | 2019 | 3652 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 2344 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2017 | 1099 | 0.030 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2014 | 225 | 0.030 |
Why?
|
| Sequestosome-1 Protein | 1 | 2012 | 39 | 0.030 |
Why?
|
| Laser Capture Microdissection | 1 | 2012 | 45 | 0.030 |
Why?
|
| Prednisone | 1 | 2015 | 1033 | 0.030 |
Why?
|
| Mice, Neurologic Mutants | 1 | 2012 | 80 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2015 | 14616 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2014 | 1189 | 0.030 |
Why?
|
| Cell Death | 1 | 2015 | 686 | 0.030 |
Why?
|
| Beclin-1 | 1 | 2012 | 88 | 0.030 |
Why?
|
| Membrane Proteins | 2 | 2014 | 2929 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2014 | 897 | 0.030 |
Why?
|
| Leukocytes | 1 | 2014 | 422 | 0.020 |
Why?
|
| Caspase 1 | 1 | 2012 | 62 | 0.020 |
Why?
|
| Fibronectins | 1 | 2012 | 205 | 0.020 |
Why?
|
| Glycoproteins | 1 | 2015 | 779 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2019 | 5759 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2024 | 3667 | 0.020 |
Why?
|
| Transplantation, Homologous | 2 | 2013 | 3044 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 1077 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2015 | 1320 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2013 | 589 | 0.020 |
Why?
|
| Protein Transport | 1 | 2014 | 737 | 0.020 |
Why?
|
| Radiography | 1 | 2016 | 1988 | 0.020 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2012 | 264 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2017 | 1320 | 0.020 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2012 | 274 | 0.020 |
Why?
|
| Transcription Factors | 2 | 2015 | 5440 | 0.020 |
Why?
|
| Lymphocytes | 1 | 2016 | 1275 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2019 | 4943 | 0.020 |
Why?
|
| HLA-DRB1 Chains | 1 | 2011 | 89 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2013 | 659 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2023 | 3181 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2015 | 2455 | 0.020 |
Why?
|
| Exercise Test | 1 | 2012 | 310 | 0.020 |
Why?
|
| Peptides | 1 | 2016 | 1504 | 0.020 |
Why?
|
| Schistosoma mansoni | 1 | 2010 | 35 | 0.020 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2011 | 189 | 0.020 |
Why?
|
| Homeodomain Proteins | 1 | 2015 | 1124 | 0.020 |
Why?
|
| Interleukin-12 Subunit p40 | 1 | 2010 | 30 | 0.020 |
Why?
|
| Schistosomiasis mansoni | 1 | 2010 | 29 | 0.020 |
Why?
|
| Multiprotein Complexes | 1 | 2012 | 385 | 0.020 |
Why?
|
| Signal Recognition Particle | 1 | 2009 | 14 | 0.020 |
Why?
|
| Chemokine CXCL9 | 1 | 2009 | 24 | 0.020 |
Why?
|
| Polymyositis | 1 | 2009 | 13 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2012 | 768 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2022 | 4480 | 0.020 |
Why?
|
| Interleukin-13 | 1 | 2010 | 130 | 0.020 |
Why?
|
| Walking | 1 | 2012 | 269 | 0.020 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2012 | 530 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2012 | 622 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2015 | 3532 | 0.020 |
Why?
|
| Cell Lineage | 1 | 2012 | 701 | 0.020 |
Why?
|
| Rats | 1 | 2018 | 6525 | 0.020 |
Why?
|
| Genetic Linkage | 1 | 2011 | 604 | 0.020 |
Why?
|
| Hyaluronoglucosaminidase | 1 | 2009 | 44 | 0.020 |
Why?
|
| CD11b Antigen | 1 | 2009 | 64 | 0.020 |
Why?
|
| Asbestos | 1 | 2008 | 37 | 0.020 |
Why?
|
| Health | 1 | 2009 | 51 | 0.020 |
Why?
|
| Coronary Artery Disease | 1 | 2016 | 883 | 0.020 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2015 | 635 | 0.020 |
Why?
|
| Transfection | 1 | 2014 | 3118 | 0.020 |
Why?
|
| Chemotaxis | 1 | 2008 | 136 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2012 | 1359 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2017 | 3919 | 0.020 |
Why?
|
| Liver Cirrhosis | 1 | 2015 | 1046 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2015 | 2238 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2011 | 1246 | 0.020 |
Why?
|
| Superoxide Dismutase | 1 | 2008 | 269 | 0.020 |
Why?
|
| Patient Selection | 1 | 2015 | 2026 | 0.020 |
Why?
|
| Carcinogens | 1 | 2008 | 391 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2013 | 1341 | 0.020 |
Why?
|
| Transcription Factor TFIIH | 1 | 2007 | 21 | 0.020 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2013 | 1260 | 0.020 |
Why?
|
| Interleukin-10 | 1 | 2010 | 484 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2017 | 3845 | 0.020 |
Why?
|
| Neovascularization, Physiologic | 1 | 2009 | 345 | 0.020 |
Why?
|
| Blotting, Northern | 1 | 2007 | 726 | 0.020 |
Why?
|
| C-Reactive Protein | 1 | 2009 | 558 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 9039 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2010 | 1052 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2013 | 2196 | 0.010 |
Why?
|
| DNA Repair | 1 | 2012 | 1910 | 0.010 |
Why?
|
| Wound Healing | 1 | 2008 | 768 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 6255 | 0.010 |
Why?
|
| Comorbidity | 1 | 2009 | 2392 | 0.010 |
Why?
|
| Quality of Life | 1 | 2017 | 4775 | 0.010 |
Why?
|
| Ethane | 1 | 2001 | 2 | 0.010 |
Why?
|
| Sulfur Oxides | 1 | 2001 | 2 | 0.010 |
Why?
|
| Pentanes | 1 | 2001 | 2 | 0.010 |
Why?
|
| Acetone | 1 | 2001 | 4 | 0.010 |
Why?
|
| Butadienes | 1 | 2001 | 36 | 0.010 |
Why?
|
| Hydrogen Sulfide | 1 | 2001 | 16 | 0.010 |
Why?
|
| Breath Tests | 1 | 2001 | 197 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2007 | 3588 | 0.010 |
Why?
|
| Neoplasms | 1 | 2016 | 15919 | 0.010 |
Why?
|